Anupam Rasayan India Limited reported robust financial performance for Q3 and 9M FY26, driven by significant year-on-year growth across consolidated and standalone metrics. Consolidated nine-month revenue grew 84% to ₹17,297 Mn. A major strategic highlight is the definitive agreement to acquire Jayhawk Fine Chemicals LLC in the U.S., aiming to build a diversified, multi-geography growth engine powered by advanced chemistries and expanding the company’s global footprint.
Financial Performance Highlights: Q3 & 9M FY26
Anupam Rasayan India Limited announced strong results for the nine months ended December 31, 2025 (9MFY26), underscoring continued growth momentum, as detailed by Managing Director Mr. Anand S Desai. The company demonstrated high year-on-year growth in key consolidated metrics.
Nine-Months Financial Summary (9MFY26 vs. 9MFY25 in ₹ Mn)
- Consolidated Total Revenue: Grew 84% Y-o-Y to ₹17,445 Mn (from ₹9,428 Mn).
- Consolidated EBITDA: Increased 53% Y-o-Y to ₹4,024 Mn (from ₹2,624 Mn), with margins at 23% (down from 28%).
- Consolidated PAT: Rose 71% Y-o-Y to ₹1,662 Mn (from ₹970 Mn).
Standalone performance was even stronger:
- Standalone Total Revenue: Jumped 130% Y-o-Y to ₹13,050 Mn.
- Standalone PAT: Soared 244% Y-o-Y to ₹1,190 Mn.
Quarterly Snapshot (Q3FY26 vs. Q3FY25 in ₹ Mn)
Quarterly results also showed positive trends:
- Consolidated Total Revenue: Increased 31% Y-o-Y to ₹5,124 Mn.
- Consolidated PAT: Grew 12% Y-o-Y to ₹606 Mn.
- Standalone PAT: Increased 150% Y-o-Y to ₹479 Mn.
Strategic Development: US Expansion via Jayhawk Acquisition
A significant strategic milestone during the period was the signing of a definitive agreement to acquire 100% equity in Jayhawk Fine Chemicals LLC, a U.S.-based specialty chemical company. The enterprise value is approximately ~$134M (total consideration ~$150M).
Jayhawk, founded in 1941 and part of the CABB Group, specializes in manufacturing performance materials (~65%) and life/crop science molecules (~35%). It reported ~$78M Revenue and ~$15M EBITDA for CY24.
Complementarity and Synergy Potential
The acquisition is expected to create substantial synergy, leveraging Anupam’s existing capabilities (like halogenation, oxidation) with Jayhawk’s expertise in Suzuki Coupling, Azo chemistry, and high-purity technology. This combination will:
- Develop full-range niche high value performance materials.
- Enable dual-site production via complementary tech platforms.
- Accelerate scale-up of the performance materials manufacturing platform.
- Provide a US-based platform for CDMO expansion and access to high-value end markets such as semiconductors, automotive/EV, and electronics.
Business Focus and Growth Drivers
The company’s growth strategy hinges on three primary drivers:
- Growth of Polymer and Pharma Product Portfolio: The Pharma segment is targeting a large ~$15B TAM with a projected ~5% CAGR (2023-28), including manufacturing KSMs for blockbuster molecules like Atorvastatin and Sitagliptin. The Polymer & Electronic chemicals segment targets a ~$10B TAM with a ~4% CAGR.
- Execution of Signed LOIs and Contracts: The total value of recent LOIs/Contracts signed stands at ₹14,646 Crores, many slated for commercialization starting in FY26.
- Expansion in Fluorination Chemistry: Backward integration through the ~26% stake in Tanfac secures key raw materials (HF and KF), enabling Anupam to target a high-value segment with a potential revenue opportunity of $220 – $260 Mn for targeted series.
Company Strengths Summary
Anupam Rasayan highlights its core strengths, including doubled manufacturing capacity in the last three years, a DSIR recognized R&D center with 90+ professionals, and a multi-pronged strategy positioning it as a partner of choice for originators and leading MNCs.
Source: BSE
